Biomarker ID | 412 |
PMID | 19131636 |
Year | 2009 |
Biomarker | Methylation Status of GSTP1+RARB2 |
Biomarker Basis | Methylation Based |
Biomolecule | Methylation |
Source | Serum |
Subjects | Humans |
Regulation | Methylated in Stage IV PCa |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include (GSTP1):-Arachidonate epoxygenase/epoxide hydrolase pathway,Multi-drug resistance factors,Glutathione conjugation,Glutathione, Prostate cancermetabolism;Pathways Include:-(RARB2)Non-small cell lung cancer,Vitamin A and carotenoid metabolism,Nuclear receptor transcription pathway,Nuclear receptors,Small cell lung cancer |
Experiment | PCA stage I-III VS PCA Stage IV |
Type of Biomarker | Prognostic |
Cohort | 40 healthy donors and 83 patients were analysed for the study. Out of 83 patients, 25 were identified from Stage (I-III) and 58 were categorised into stage IV. 0 out of 25 showed methylation in GSTP1. 11 out of 58 showed methylation in RARB. |
Senstivity | 89% |
Specificity | NA |
AUC | NA |
Accuracy | 63% |
Level Of Significance | p=0.019 |
Method Used | methylation-specific PCR assay |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | GSTP1, RARB2 |